News stories about Vital Therapies (NASDAQ:VTL) have been trending positive recently, Alpha One Sentiment Analysis reports. The research group, a service of Accern, identifies positive and negative media coverage by analyzing more than twenty million news and blog sources in real time. Alpha One ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Vital Therapies earned a coverage optimism score of 0.31 on Alpha One’s scale. Alpha One also gave media stories about the company an impact score of 100 out of 100, meaning that recent media coverage is extremely likely to have an effect on the company’s share price in the immediate future.

A number of equities analysts have commented on the stock. Zacks Investment Research upgraded shares of Vital Therapies from a “sell” rating to a “hold” rating in a research report on Thursday, April 6th. Canaccord Genuity set a $10.00 price objective on shares of Vital Therapies and gave the stock a “buy” rating in a research report on Monday, January 2nd. Finally, BTIG Research restated a “hold” rating on shares of Vital Therapies in a research report on Friday, March 10th.

Shares of Vital Therapies (NASDAQ:VTL) traded down 2.78% during trading on Friday, hitting $3.50. 66,550 shares of the stock were exchanged. Vital Therapies has a 12-month low of $3.50 and a 12-month high of $9.25. The stock’s market cap is $112.50 million. The stock has a 50-day moving average of $4.07 and a 200 day moving average of $4.91.

Vital Therapies (NASDAQ:VTL) last issued its quarterly earnings results on Tuesday, March 7th. The company reported ($0.37) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.36) by $0.01. During the same period in the previous year, the firm earned ($0.34) earnings per share. Equities analysts predict that Vital Therapies will post ($1.51) earnings per share for the current fiscal year.

In related news, Director Muneer A. Satter purchased 3,750,000 shares of the company’s stock in a transaction that occurred on Monday, March 27th. The shares were purchased at an average price of $4.00 per share, with a total value of $15,000,000.00. The acquisition was disclosed in a document filed with the SEC, which is available at this link. Company insiders own 29.88% of the company’s stock.

ILLEGAL ACTIVITY WARNING: This report was reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this report on another site, it was stolen and republished in violation of US & international copyright and trademark legislation. The correct version of this report can be accessed at

About Vital Therapies

Vital Therapies, Inc is a biotherapeutic company. The Company is focused on developing a human hepatic cell-based treatment targeting acute forms of liver failure. Its product candidate, the ELAD System, is an extracorporeal human allogeneic cellular liver therapy designed to allow the patient’s liver to regenerate to a healthy state, or to stabilize the patient until transplant.

5 Day Chart for NASDAQ:VTL

Receive News & Stock Ratings for Vital Therapies Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vital Therapies Inc and related stocks with our FREE daily email newsletter.